Surgical treatment for acute aortic dissection with coronary malperfusion in Japan: Nationwide database analysis

日本急性主动脉夹层合并冠状动脉灌注不良的外科治疗:全国数据库分析

阅读:1

Abstract

OBJECTIVE: To assess the surgical outcomes of acute aortic dissection (AAD) with coronary malperfusion (CM) in Japan through the Japan Cardiovascular Surgery Database. METHODS: Between 2019 and 2021, 15,509 patients underwent surgical treatment for AAD. CM occurred in 304 (2.0%), of which 188 were analyzed. RESULTS: The mean age of patients was 65 ± 11.8 years. Preoperative acute myocardial infarction, cardiopulmonary arrest, and mechanical circulatory support (MCS) were found in 49.5%, 16.5%, and 9.6%, respectively. The 30-day operative mortality rate was 33.0%. The left CM (33.5%) was associated with greater mortality rates (41.3%), particularly as Neri classification advanced to type B and type C. Conversely, right CM (56.4%) had a lower mortality rate (25.0%), regardless of Neri classification. Preoperative percutaneous coronary intervention was performed in 14.9% and concomitant coronary artery bypass grafting was performed in 57.4%. The 30-day operative mortality rate for coronary intervention showed no difference between percutaneous coronary intervention (41.7%) and coronary artery bypass grafting (38.0%), regardless of Neri classification. The median time from onset to coronary reperfusion was 361.5 minutes. Preoperative acute myocardial infarction, cardiopulmonary arrest, and the requirement for MCS as independent risk factors for 30-day operative mortality. CONCLUSIONS: The surgical mortality rate for AAD with CM remains high, particularly in cases with left CM, with this trend becoming more pronounced as the Neri's classification advanced to type B and type C. Patients in critical conditions, such as those requiring cardiopulmonary resuscitation or MCS, were at significantly greater risk of mortality.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。